LPL Financial
BCTX

LPL Financial’s Briacell Therapeutics BCTX Stock Holding History

LPL Financial’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-262
Closed -$22.2K – 5365
2024
Q4 		$22.2K Buy
262
+60
+30% +$7.19K ﹤0.01% 5190
2024
Q3 		$37.5K Buy
202
+125
+162% +$14K ﹤0.01% 5026
2024
Q2 		$13.2K Buy
+77
New +$21.8K ﹤0.01% 4960

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

LPL Financial's BCTX Position: Q1 2025 in Review

LPL Financial sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 262 shares — an estimated $22.2K sold.

LPL Financial first reported a position in BCTX in Q2 2024 and held it in 3 quarters. The position peaked at $37.5K in Q3 2024. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • LPL Financial reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LPL Financial sold 262 Briacell Therapeutics shares in Q1 2025, an estimated $22.2K.
  • LPL Financial first reported a position in Briacell Therapeutics in Q2 2024 and held it in 3 quarters.
  • LPL Financial's Briacell Therapeutics position peaked at $37.5K in Q3 2024.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on LPL Financial's 13F filing for Q1 2025, filed 7 May 2025.